Key facts
- Truveris’s last known valuation is $32.0M.
- It has raised $68.7M; the latest was Later Stage VC ($15.0M) in May 2024.
- Notable investors include First Round Capital, Canaan Partners, KBW Ventures, Revelation Partners, McKesson Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Truveris
- ·The full record, as it builds
Funding rounds
No funding rounds for Truveris are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Truveris
Developer of a health information technology platform designed to offer prescription benefit plans. The company's platform provides specific and actionable insights and assists payers of pharmacy benefits, validates claim payment accuracy, ensures regulatory compliance, and manages pharmacy spending with their scalable and automated implement claims analysis engine, enabling payers, brokers, and manufacturers to effectively and efficiently manage the complexity and rising costs of prescription drugs, reduce costs and improve access.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2009
- Employees
- 93
- Website
- truveris.com/
- Ownership
- Privately Held (backing)
Truveris doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Truveris shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Truveris in its N-PORT filings yet. We sweep new filings monthly.